<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842462</url>
  </required_header>
  <id_info>
    <org_study_id>NHFOV study group</org_study_id>
    <nct_id>NCT03842462</nct_id>
  </id_info>
  <brief_title>NHFOV vs NIPPV vs nCPAP in Preterm Infants With Respiratory Distress Syndrome</brief_title>
  <official_title>NHFOV vs NIPPV vs nCPAP in Preterm Infants With Respiratory Distress Syndrome: A Multi-center, Prospective, Randomized, Controlled Clinical Superior Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiulongpo No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiulongpo No.1 People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, multi-center, three-arms,parallel, randomized, controlled trial&#xD;
      with a superiority design,conducted in China. The investigators conduct this multi-centre,&#xD;
      randomized, controlled trial to test the hypothesis that NHFOV is more effective than nCPAP&#xD;
      or NIPPV in the treatment of respiratory distress syndrome (RDS) in infants with a&#xD;
      gestational age of less than 30 weeks or a birth weight of less than 1500g when used as a&#xD;
      primary noninvasive ventilation (NIV) mode.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm infants are eligible to the study if they they match the following inclusion&#xD;
      criteria: (1) Gestational age (GA) less than 30 weeks or Birth weight less than 1500g; (2)&#xD;
      They have a diagnose of RDS, and RDS Silverman score﹥5; (3) Informed parental consent has&#xD;
      been obtained.&#xD;
&#xD;
      Neonates will be randomized and assigned either to nCPAP, NIPPV or NHFOV arms with a 1:1:1&#xD;
      ratio, when patients fulfill all inclusion criteria. Randomization cannot be done earlier.&#xD;
      Simple randomization will be done according to a computer-generated random number table and&#xD;
      will be posted in a specific secured website 24/7 available. Twins will be allocated in the&#xD;
      same treatment group. Infants randomized to one arm cannot crossover to the other or&#xD;
      vice-versa during the study.&#xD;
&#xD;
      For all the groups, if the fraction of inspired oxygen (FiO2) requirement is persistently&#xD;
      higher than 0.35-0.40 per target SpO2 89-94% and/or dyspnoea defined by Silverman score &gt; 6&#xD;
      after starting the respiratory support, newborns receive Surfactant by &quot;INSURE&quot; technique,&#xD;
      involving endotracheal intubation by direct laryngoscopic vision, endotracheal administration&#xD;
      of surfactant (Curosurf, Chiesi Pharmaceutics, Parma, Italy) 200 mg/kg and finally&#xD;
      extubation.&#xD;
&#xD;
      After the administration of surfactant, if FiO2 requirement is persistently &gt;0.4 to keep SpO2&#xD;
      89-94% or severe apnea episodes are present (defined as recurrent apnea with &gt;3 episodes/h&#xD;
      associated with heart rate &lt;100/min or a single episode of apnea requiring bag and mask&#xD;
      ventilation within a 24-hour period ) or at the blood gas (arterial or free-flowing capillary&#xD;
      blood) PaCO2&gt;60 mmHg and potential of hydrogen (pH)&lt;7.20 obtained at least 1 hour after&#xD;
      commencement of the assigned treatment, newborns are intubated and mechanically ventilated.&#xD;
      For all the newborns enrolled in the study, arterial or free-flowing capillary blood gas is&#xD;
      checked every 6-12 hours, a cerebral and cardiac ultrasound screening is performed within 24&#xD;
      hrs. Further controls follow the routine of the ward.&#xD;
&#xD;
      The study intervention (nCPAP, NIPPV or NHFOV) will be stopped when the above-described&#xD;
      minimum parameters are reached and maintained for at least 48h with the following: (1)&#xD;
      FiO2≤0.25; (2) Silverman score &lt;3; (3)no apneas or bradycardia without spontaneous&#xD;
      recovery.If a baby will desaturate (SpO2&lt;85% with FiO2&gt;25%) or has relevant dyspnea&#xD;
      (Silverman≧3) or more than 3 apneas/d, the intervention (CPAP, NIPPV or NHFOV) will be&#xD;
      restarted for at least 48h and then re-evaluated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">May 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment failure within 72 hours after randomization 72 hours after randomization</measure>
    <time_frame>within 72 hours after randomization</time_frame>
    <description>need for invasive mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of airleaks(pneumothorax and/or pneumomediastinum) occurred during noninvasive respiratory support</measure>
    <time_frame>during noninvasive respiratory support</time_frame>
    <description>determined by the treating clinician by the treating clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks of postmenstrual age</time_frame>
    <description>defined according to the NICHD definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of retinopathy of prematurity (ROP)</measure>
    <time_frame>Within 6 months after birth</time_frame>
    <description>≥ 2nd stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of necrotizing enterocolitis (NEC)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>≥ 2nd stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intraventricular hemorrhage</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>≥ 3nd grade</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of thick secretions causing an airway obstruction.</measure>
    <time_frame>during noninvasive respiratory support</time_frame>
    <description>determined by the treating clinician by the treating clinician</description>
  </other_outcome>
  <other_outcome>
    <measure>days of hospitalization</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>days</description>
  </other_outcome>
  <other_outcome>
    <measure>duration of noninvasive respiratory support</measure>
    <time_frame>duration of noninvasive respiratory support</time_frame>
    <description>hours</description>
  </other_outcome>
  <other_outcome>
    <measure>days on supplemental oxygen</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>days</description>
  </other_outcome>
  <other_outcome>
    <measure>need for surfactant and caffeine treatment</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>determined by the treating clinician by the treating clinician</description>
  </other_outcome>
  <other_outcome>
    <measure>in-hospital mortality</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Death</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of nasal trauma</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>determined by the treating clinician by the treating clinician</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">684</enrollment>
  <condition>Preterm Infant</condition>
  <arm_group>
    <arm_group_label>nCPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIPPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHFOV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:&#xD;
a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nCPAP</intervention_name>
    <description>infants receive primary non-invasive respiratory support by mean of nCPAP</description>
    <arm_group_label>nCPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NIPPV</intervention_name>
    <description>infants receive primary non-invasive respiratory support by mean of NIPPV</description>
    <arm_group_label>NIPPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NHFOV</intervention_name>
    <description>infants receive primary non-invasive respiratory support by mean of NHFOV</description>
    <arm_group_label>NHFOV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age (GA) of less than 30 weeks or birth weight less than 1500g&#xD;
&#xD;
          -  Clinical diagnose of RDS&#xD;
&#xD;
          -  Parental consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intubated for resuscitation or for other reasons at birth&#xD;
&#xD;
          -  Major congenital malformations or known complex congenital heart disease&#xD;
&#xD;
          -  No parental consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Shi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingwang Zhu, MD</last_name>
    <phone>15084335697</phone>
    <email>15084335697@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Shi, PhD</last_name>
    <phone>13508300283</phone>
    <email>petshi530@vip.163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Bao, MD</last_name>
      <phone>+8618623298567</phone>
      <email>cqbl0046@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Women and Children Health Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>401120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyun Zhong, MD</last_name>
      <phone>+8613883519380</phone>
      <email>13883519380@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Yi, MD</last_name>
      <phone>+8615178969566</phone>
      <email>yimingd123@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guiyang Maternity and Child Health Care Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Liu, PhD</last_name>
      <phone>0851-5965786</phone>
      <email>liulingped@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Children's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiqing Sun, MD</last_name>
      <phone>0371-85515555</phone>
      <email>s_huiqing@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Children's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xirong Gao, MD</last_name>
      <phone>0731-85356114</phone>
      <email>gaoxirong@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chengdu Women and Children's Central Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Ju, MD</last_name>
      <phone>028-65021687</phone>
      <email>jurong123@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kunming Children's Hospital, Kunming</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yangfang Li, MD</last_name>
      <phone>0871-63309191</phone>
      <email>lyf61@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiulongpo No.1 People's Hospital</investigator_affiliation>
    <investigator_full_name>Xingwang Zhu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Preterm Infant</keyword>
  <keyword>Respiratory distress syndrome</keyword>
  <keyword>nasal continuous positive airway pressure</keyword>
  <keyword>noninvasive intermittent positive airway pressure</keyword>
  <keyword>noninvasive high-frequency oscillatory ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

